nodes	percent_of_prediction	percent_of_DWPC	metapath
Prazosin—CYP1A1—kidney cancer	0.225	0.653	CbGaD
Prazosin—ABCB1—kidney cancer	0.12	0.347	CbGaD
Prazosin—SLC22A3—Vincristine—kidney cancer	0.0479	0.1	CbGbCtD
Prazosin—ORM1—Erlotinib—kidney cancer	0.0434	0.0909	CbGbCtD
Prazosin—ABCG2—Pazopanib—kidney cancer	0.0372	0.0777	CbGbCtD
Prazosin—ABCG2—Dactinomycin—kidney cancer	0.034	0.0711	CbGbCtD
Prazosin—SLC22A2—Vinblastine—kidney cancer	0.0288	0.0603	CbGbCtD
Prazosin—ABCG2—Erlotinib—kidney cancer	0.0265	0.0555	CbGbCtD
Prazosin—ABCB1—Temsirolimus—kidney cancer	0.0255	0.0534	CbGbCtD
Prazosin—KCNH2—Sunitinib—kidney cancer	0.0252	0.0528	CbGbCtD
Prazosin—CYP1A1—Erlotinib—kidney cancer	0.0245	0.0512	CbGbCtD
Prazosin—ABCG2—Paclitaxel—kidney cancer	0.0243	0.0508	CbGbCtD
Prazosin—ABCG2—Sorafenib—kidney cancer	0.0216	0.0451	CbGbCtD
Prazosin—ABCG2—Vincristine—kidney cancer	0.0209	0.0438	CbGbCtD
Prazosin—ABCG2—Sunitinib—kidney cancer	0.0175	0.0365	CbGbCtD
Prazosin—ABCB1—Pazopanib—kidney cancer	0.0134	0.028	CbGbCtD
Prazosin—ABCG2—Doxorubicin—kidney cancer	0.0131	0.0274	CbGbCtD
Prazosin—ABCB1—Dactinomycin—kidney cancer	0.0123	0.0256	CbGbCtD
Prazosin—ABCB1—Gemcitabine—kidney cancer	0.00969	0.0203	CbGbCtD
Prazosin—ABCB1—Erlotinib—kidney cancer	0.00956	0.02	CbGbCtD
Prazosin—ABCB1—Paclitaxel—kidney cancer	0.00875	0.0183	CbGbCtD
Prazosin—ABCB1—Sorafenib—kidney cancer	0.00777	0.0163	CbGbCtD
Prazosin—ABCB1—Vinblastine—kidney cancer	0.00768	0.0161	CbGbCtD
Prazosin—ABCB1—Vincristine—kidney cancer	0.00755	0.0158	CbGbCtD
Prazosin—ABCB1—Sunitinib—kidney cancer	0.0063	0.0132	CbGbCtD
Prazosin—SLC22A2—nephron—kidney cancer	0.00525	0.194	CbGeAlD
Prazosin—ABCB1—Doxorubicin—kidney cancer	0.00472	0.00987	CbGbCtD
Prazosin—KCNH6—nephron tubule—kidney cancer	0.00191	0.0708	CbGeAlD
Prazosin—KCNH6—renal system—kidney cancer	0.00174	0.0643	CbGeAlD
Prazosin—KCNH6—kidney—kidney cancer	0.00168	0.0622	CbGeAlD
Prazosin—SLC22A2—nephron tubule—kidney cancer	0.00113	0.0419	CbGeAlD
Prazosin—SLC22A2—renal system—kidney cancer	0.00103	0.0381	CbGeAlD
Prazosin—SLC22A2—kidney—kidney cancer	0.000995	0.0368	CbGeAlD
Prazosin—ADRA1B—renal system—kidney cancer	0.000986	0.0364	CbGeAlD
Prazosin—SLC22A2—cortex of kidney—kidney cancer	0.00097	0.0358	CbGeAlD
Prazosin—ADRA1B—kidney—kidney cancer	0.000953	0.0352	CbGeAlD
Prazosin—SLC22A1—renal system—kidney cancer	0.000727	0.0269	CbGeAlD
Prazosin—SLC22A1—kidney—kidney cancer	0.000703	0.026	CbGeAlD
Prazosin—HTR1D—kidney—kidney cancer	0.000697	0.0258	CbGeAlD
Prazosin—SLC22A3—renal system—kidney cancer	0.000695	0.0257	CbGeAlD
Prazosin—SLC22A3—kidney—kidney cancer	0.000672	0.0248	CbGeAlD
Prazosin—SLC22A3—gonad—kidney cancer	0.000623	0.023	CbGeAlD
Prazosin—HTR1A—renal system—kidney cancer	0.000601	0.0222	CbGeAlD
Prazosin—ADRA1A—renal system—kidney cancer	0.000554	0.0205	CbGeAlD
Prazosin—KCNH2—renal system—kidney cancer	0.000535	0.0198	CbGeAlD
Prazosin—ABCG2—nephron tubule—kidney cancer	0.000523	0.0193	CbGeAlD
Prazosin—KCNH2—cardiac atrium—kidney cancer	0.000479	0.0177	CbGeAlD
Prazosin—CYP1A1—renal system—kidney cancer	0.000452	0.0167	CbGeAlD
Prazosin—Terazosin—ABCB1—kidney cancer	0.00044	0.573	CrCbGaD
Prazosin—CYP1A1—kidney—kidney cancer	0.000437	0.0161	CbGeAlD
Prazosin—CYP1A1—cardiac atrium—kidney cancer	0.000405	0.015	CbGeAlD
Prazosin—ADRA2A—cortex of kidney—kidney cancer	0.000396	0.0147	CbGeAlD
Prazosin—ADRA2A—gonad—kidney cancer	0.000378	0.014	CbGeAlD
Prazosin—ADRA2A—cardiac atrium—kidney cancer	0.000377	0.0139	CbGeAlD
Prazosin—Doxazosin—ABCB1—kidney cancer	0.000327	0.427	CrCbGaD
Prazosin—Headache—Pazopanib—kidney cancer	0.000259	0.00257	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Sorafenib—kidney cancer	0.000258	0.00256	CcSEcCtD
Prazosin—Oedema—Dactinomycin—kidney cancer	0.000258	0.00256	CcSEcCtD
Prazosin—Body temperature increased—Everolimus—kidney cancer	0.000258	0.00256	CcSEcCtD
Prazosin—ABCB1—nephron tubule—kidney cancer	0.000258	0.00954	CbGeAlD
Prazosin—Angina pectoris—Capecitabine—kidney cancer	0.000258	0.00256	CcSEcCtD
Prazosin—Sweating increased—Capecitabine—kidney cancer	0.000258	0.00256	CcSEcCtD
Prazosin—Vertigo—Vincristine—kidney cancer	0.000254	0.00252	CcSEcCtD
Prazosin—Abdominal discomfort—Capecitabine—kidney cancer	0.000254	0.00252	CcSEcCtD
Prazosin—Dyspnoea—Sorafenib—kidney cancer	0.000253	0.00251	CcSEcCtD
Prazosin—Body temperature increased—Erlotinib—kidney cancer	0.000249	0.00247	CcSEcCtD
Prazosin—Ill-defined disorder—Gemcitabine—kidney cancer	0.000249	0.00247	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Sunitinib—kidney cancer	0.000249	0.00247	CcSEcCtD
Prazosin—Insomnia—Sunitinib—kidney cancer	0.000247	0.00245	CcSEcCtD
Prazosin—Nausea—Pazopanib—kidney cancer	0.000246	0.00244	CcSEcCtD
Prazosin—Paraesthesia—Sunitinib—kidney cancer	0.000245	0.00243	CcSEcCtD
Prazosin—Fatigue—Sorafenib—kidney cancer	0.000244	0.00243	CcSEcCtD
Prazosin—Dyspnoea—Sunitinib—kidney cancer	0.000243	0.00241	CcSEcCtD
Prazosin—Pain—Sorafenib—kidney cancer	0.000242	0.00241	CcSEcCtD
Prazosin—Constipation—Sorafenib—kidney cancer	0.000242	0.00241	CcSEcCtD
Prazosin—Malaise—Gemcitabine—kidney cancer	0.000242	0.0024	CcSEcCtD
Prazosin—Hypersensitivity—Vinblastine—kidney cancer	0.000242	0.0024	CcSEcCtD
Prazosin—Hypersensitivity—Everolimus—kidney cancer	0.000241	0.00239	CcSEcCtD
Prazosin—Tinnitus—Paclitaxel—kidney cancer	0.000241	0.00239	CcSEcCtD
Prazosin—Flushing—Paclitaxel—kidney cancer	0.000239	0.00238	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Dactinomycin—kidney cancer	0.000235	0.00233	CcSEcCtD
Prazosin—Asthenia—Vinblastine—kidney cancer	0.000235	0.00233	CcSEcCtD
Prazosin—Fatigue—Sunitinib—kidney cancer	0.000235	0.00233	CcSEcCtD
Prazosin—ABCB1—renal system—kidney cancer	0.000235	0.00867	CbGeAlD
Prazosin—Asthenia—Everolimus—kidney cancer	0.000234	0.00233	CcSEcCtD
Prazosin—Constipation—Sunitinib—kidney cancer	0.000233	0.00231	CcSEcCtD
Prazosin—Pain—Sunitinib—kidney cancer	0.000233	0.00231	CcSEcCtD
Prazosin—Pruritus—Everolimus—kidney cancer	0.000231	0.00229	CcSEcCtD
Prazosin—Oedema—Vincristine—kidney cancer	0.000231	0.00229	CcSEcCtD
Prazosin—Arthralgia—Gemcitabine—kidney cancer	0.000228	0.00227	CcSEcCtD
Prazosin—Alopecia—Paclitaxel—kidney cancer	0.000228	0.00226	CcSEcCtD
Prazosin—ABCB1—kidney—kidney cancer	0.000227	0.00838	CbGeAlD
Prazosin—Asthenia—Erlotinib—kidney cancer	0.000226	0.00224	CcSEcCtD
Prazosin—Discomfort—Gemcitabine—kidney cancer	0.000226	0.00224	CcSEcCtD
Prazosin—Urticaria—Sorafenib—kidney cancer	0.000225	0.00223	CcSEcCtD
Prazosin—Diarrhoea—Vinblastine—kidney cancer	0.000224	0.00223	CcSEcCtD
Prazosin—Body temperature increased—Sorafenib—kidney cancer	0.000224	0.00222	CcSEcCtD
Prazosin—Diarrhoea—Everolimus—kidney cancer	0.000223	0.00222	CcSEcCtD
Prazosin—Hyperhidrosis—Vincristine—kidney cancer	0.000223	0.00221	CcSEcCtD
Prazosin—Pruritus—Erlotinib—kidney cancer	0.000223	0.00221	CcSEcCtD
Prazosin—Fatigue—Dactinomycin—kidney cancer	0.000223	0.00221	CcSEcCtD
Prazosin—Epistaxis—Capecitabine—kidney cancer	0.000222	0.00221	CcSEcCtD
Prazosin—ABCB1—cortex of kidney—kidney cancer	0.000221	0.00816	CbGeAlD
Prazosin—Pain—Dactinomycin—kidney cancer	0.000221	0.00219	CcSEcCtD
Prazosin—Tension—Paclitaxel—kidney cancer	0.00022	0.00219	CcSEcCtD
Prazosin—Oedema—Gemcitabine—kidney cancer	0.000219	0.00217	CcSEcCtD
Prazosin—Eye pain—Doxorubicin—kidney cancer	0.000219	0.00217	CcSEcCtD
Prazosin—Nervousness—Paclitaxel—kidney cancer	0.000218	0.00216	CcSEcCtD
Prazosin—Dizziness—Vinblastine—kidney cancer	0.000217	0.00215	CcSEcCtD
Prazosin—Dizziness—Everolimus—kidney cancer	0.000216	0.00214	CcSEcCtD
Prazosin—Body temperature increased—Sunitinib—kidney cancer	0.000216	0.00214	CcSEcCtD
Prazosin—Diarrhoea—Erlotinib—kidney cancer	0.000216	0.00214	CcSEcCtD
Prazosin—Bradycardia—Capecitabine—kidney cancer	0.000216	0.00214	CcSEcCtD
Prazosin—Feeling abnormal—Dactinomycin—kidney cancer	0.000213	0.00211	CcSEcCtD
Prazosin—Vision blurred—Paclitaxel—kidney cancer	0.000212	0.0021	CcSEcCtD
Prazosin—Hyperhidrosis—Gemcitabine—kidney cancer	0.000212	0.0021	CcSEcCtD
Prazosin—ABCB1—gonad—kidney cancer	0.00021	0.00778	CbGeAlD
Prazosin—Musculoskeletal discomfort—Vincristine—kidney cancer	0.00021	0.00209	CcSEcCtD
Prazosin—Hypersensitivity—Sorafenib—kidney cancer	0.000209	0.00207	CcSEcCtD
Prazosin—Insomnia—Vincristine—kidney cancer	0.000209	0.00207	CcSEcCtD
Prazosin—Vomiting—Vinblastine—kidney cancer	0.000208	0.00207	CcSEcCtD
Prazosin—Dizziness—Erlotinib—kidney cancer	0.000208	0.00207	CcSEcCtD
Prazosin—Ill-defined disorder—Paclitaxel—kidney cancer	0.000208	0.00207	CcSEcCtD
Prazosin—Vomiting—Everolimus—kidney cancer	0.000208	0.00206	CcSEcCtD
Prazosin—Paraesthesia—Vincristine—kidney cancer	0.000207	0.00206	CcSEcCtD
Prazosin—Rash—Everolimus—kidney cancer	0.000206	0.00204	CcSEcCtD
Prazosin—Dermatitis—Everolimus—kidney cancer	0.000206	0.00204	CcSEcCtD
Prazosin—Headache—Vinblastine—kidney cancer	0.000205	0.00204	CcSEcCtD
Prazosin—Headache—Everolimus—kidney cancer	0.000205	0.00203	CcSEcCtD
Prazosin—Body temperature increased—Dactinomycin—kidney cancer	0.000204	0.00203	CcSEcCtD
Prazosin—Asthenia—Sorafenib—kidney cancer	0.000203	0.00202	CcSEcCtD
Prazosin—Malaise—Paclitaxel—kidney cancer	0.000203	0.00201	CcSEcCtD
Prazosin—Vertigo—Paclitaxel—kidney cancer	0.000202	0.002	CcSEcCtD
Prazosin—Syncope—Paclitaxel—kidney cancer	0.000201	0.002	CcSEcCtD
Prazosin—Hypersensitivity—Sunitinib—kidney cancer	0.000201	0.00199	CcSEcCtD
Prazosin—Pruritus—Sorafenib—kidney cancer	0.000201	0.00199	CcSEcCtD
Prazosin—Vomiting—Erlotinib—kidney cancer	0.0002	0.00199	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Gemcitabine—kidney cancer	0.000199	0.00198	CcSEcCtD
Prazosin—Fatigue—Vincristine—kidney cancer	0.000199	0.00197	CcSEcCtD
Prazosin—Rash—Erlotinib—kidney cancer	0.000199	0.00197	CcSEcCtD
Prazosin—Dermatitis—Erlotinib—kidney cancer	0.000199	0.00197	CcSEcCtD
Prazosin—Palpitations—Paclitaxel—kidney cancer	0.000198	0.00197	CcSEcCtD
Prazosin—Insomnia—Gemcitabine—kidney cancer	0.000198	0.00196	CcSEcCtD
Prazosin—Headache—Erlotinib—kidney cancer	0.000197	0.00196	CcSEcCtD
Prazosin—Tinnitus—Capecitabine—kidney cancer	0.000197	0.00196	CcSEcCtD
Prazosin—Loss of consciousness—Paclitaxel—kidney cancer	0.000197	0.00196	CcSEcCtD
Prazosin—Constipation—Vincristine—kidney cancer	0.000197	0.00196	CcSEcCtD
Prazosin—Pain—Vincristine—kidney cancer	0.000197	0.00196	CcSEcCtD
Prazosin—Paraesthesia—Gemcitabine—kidney cancer	0.000197	0.00195	CcSEcCtD
Prazosin—Flushing—Capecitabine—kidney cancer	0.000196	0.00195	CcSEcCtD
Prazosin—Asthenia—Sunitinib—kidney cancer	0.000196	0.00194	CcSEcCtD
Prazosin—Dyspnoea—Gemcitabine—kidney cancer	0.000195	0.00194	CcSEcCtD
Prazosin—Nausea—Vinblastine—kidney cancer	0.000195	0.00193	CcSEcCtD
Prazosin—Somnolence—Gemcitabine—kidney cancer	0.000195	0.00193	CcSEcCtD
Prazosin—Nausea—Everolimus—kidney cancer	0.000194	0.00192	CcSEcCtD
Prazosin—Diarrhoea—Sorafenib—kidney cancer	0.000194	0.00192	CcSEcCtD
Prazosin—Pruritus—Sunitinib—kidney cancer	0.000193	0.00192	CcSEcCtD
Prazosin—Arthralgia—Paclitaxel—kidney cancer	0.000191	0.0019	CcSEcCtD
Prazosin—Hypersensitivity—Dactinomycin—kidney cancer	0.00019	0.00189	CcSEcCtD
Prazosin—Discomfort—Paclitaxel—kidney cancer	0.000189	0.00187	CcSEcCtD
Prazosin—Fatigue—Gemcitabine—kidney cancer	0.000189	0.00187	CcSEcCtD
Prazosin—Dizziness—Sorafenib—kidney cancer	0.000187	0.00186	CcSEcCtD
Prazosin—Pain—Gemcitabine—kidney cancer	0.000187	0.00186	CcSEcCtD
Prazosin—Constipation—Gemcitabine—kidney cancer	0.000187	0.00186	CcSEcCtD
Prazosin—Nausea—Erlotinib—kidney cancer	0.000187	0.00186	CcSEcCtD
Prazosin—Alopecia—Capecitabine—kidney cancer	0.000187	0.00186	CcSEcCtD
Prazosin—Dry mouth—Paclitaxel—kidney cancer	0.000187	0.00186	CcSEcCtD
Prazosin—Diarrhoea—Sunitinib—kidney cancer	0.000187	0.00185	CcSEcCtD
Prazosin—Asthenia—Dactinomycin—kidney cancer	0.000185	0.00184	CcSEcCtD
Prazosin—Oedema—Paclitaxel—kidney cancer	0.000183	0.00182	CcSEcCtD
Prazosin—Body temperature increased—Vincristine—kidney cancer	0.000182	0.00181	CcSEcCtD
Prazosin—Dizziness—Sunitinib—kidney cancer	0.00018	0.00179	CcSEcCtD
Prazosin—Feeling abnormal—Gemcitabine—kidney cancer	0.00018	0.00179	CcSEcCtD
Prazosin—Shock—Paclitaxel—kidney cancer	0.00018	0.00179	CcSEcCtD
Prazosin—Vomiting—Sorafenib—kidney cancer	0.00018	0.00179	CcSEcCtD
Prazosin—Orthostatic hypotension—Doxorubicin—kidney cancer	0.00018	0.00179	CcSEcCtD
Prazosin—Tachycardia—Paclitaxel—kidney cancer	0.000179	0.00177	CcSEcCtD
Prazosin—Rash—Sorafenib—kidney cancer	0.000179	0.00177	CcSEcCtD
Prazosin—Dermatitis—Sorafenib—kidney cancer	0.000179	0.00177	CcSEcCtD
Prazosin—Headache—Sorafenib—kidney cancer	0.000178	0.00176	CcSEcCtD
Prazosin—Hyperhidrosis—Paclitaxel—kidney cancer	0.000177	0.00176	CcSEcCtD
Prazosin—Diarrhoea—Dactinomycin—kidney cancer	0.000177	0.00175	CcSEcCtD
Prazosin—Vision blurred—Capecitabine—kidney cancer	0.000174	0.00172	CcSEcCtD
Prazosin—Vomiting—Sunitinib—kidney cancer	0.000173	0.00172	CcSEcCtD
Prazosin—Body temperature increased—Gemcitabine—kidney cancer	0.000173	0.00172	CcSEcCtD
Prazosin—Rash—Sunitinib—kidney cancer	0.000172	0.00171	CcSEcCtD
Prazosin—Dermatitis—Sunitinib—kidney cancer	0.000172	0.00171	CcSEcCtD
Prazosin—Ill-defined disorder—Capecitabine—kidney cancer	0.000171	0.0017	CcSEcCtD
Prazosin—Headache—Sunitinib—kidney cancer	0.000171	0.0017	CcSEcCtD
Prazosin—Hypersensitivity—Vincristine—kidney cancer	0.00017	0.00169	CcSEcCtD
Prazosin—Nausea—Sorafenib—kidney cancer	0.000168	0.00167	CcSEcCtD
Prazosin—Pancreatitis—Doxorubicin—kidney cancer	0.000167	0.00166	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Paclitaxel—kidney cancer	0.000167	0.00166	CcSEcCtD
Prazosin—Malaise—Capecitabine—kidney cancer	0.000166	0.00165	CcSEcCtD
Prazosin—Angina pectoris—Doxorubicin—kidney cancer	0.000166	0.00165	CcSEcCtD
Prazosin—Insomnia—Paclitaxel—kidney cancer	0.000166	0.00164	CcSEcCtD
Prazosin—Vertigo—Capecitabine—kidney cancer	0.000166	0.00164	CcSEcCtD
Prazosin—Asthenia—Vincristine—kidney cancer	0.000166	0.00164	CcSEcCtD
Prazosin—Syncope—Capecitabine—kidney cancer	0.000165	0.00164	CcSEcCtD
Prazosin—Paraesthesia—Paclitaxel—kidney cancer	0.000165	0.00163	CcSEcCtD
Prazosin—Vomiting—Dactinomycin—kidney cancer	0.000164	0.00163	CcSEcCtD
Prazosin—Dyspnoea—Paclitaxel—kidney cancer	0.000163	0.00162	CcSEcCtD
Prazosin—Somnolence—Paclitaxel—kidney cancer	0.000163	0.00162	CcSEcCtD
Prazosin—Palpitations—Capecitabine—kidney cancer	0.000163	0.00162	CcSEcCtD
Prazosin—Rash—Dactinomycin—kidney cancer	0.000163	0.00162	CcSEcCtD
Prazosin—Nausea—Sunitinib—kidney cancer	0.000162	0.00161	CcSEcCtD
Prazosin—Loss of consciousness—Capecitabine—kidney cancer	0.000162	0.00161	CcSEcCtD
Prazosin—Fatigue—Paclitaxel—kidney cancer	0.000158	0.00157	CcSEcCtD
Prazosin—Diarrhoea—Vincristine—kidney cancer	0.000158	0.00157	CcSEcCtD
Prazosin—Pollakiuria—Doxorubicin—kidney cancer	0.000158	0.00156	CcSEcCtD
Prazosin—Asthenia—Gemcitabine—kidney cancer	0.000157	0.00156	CcSEcCtD
Prazosin—Arthralgia—Capecitabine—kidney cancer	0.000157	0.00156	CcSEcCtD
Prazosin—Constipation—Paclitaxel—kidney cancer	0.000157	0.00156	CcSEcCtD
Prazosin—Pain—Paclitaxel—kidney cancer	0.000157	0.00156	CcSEcCtD
Prazosin—Discomfort—Capecitabine—kidney cancer	0.000155	0.00154	CcSEcCtD
Prazosin—Pruritus—Gemcitabine—kidney cancer	0.000155	0.00154	CcSEcCtD
Prazosin—Dry mouth—Capecitabine—kidney cancer	0.000153	0.00152	CcSEcCtD
Prazosin—Nausea—Dactinomycin—kidney cancer	0.000153	0.00152	CcSEcCtD
Prazosin—Dizziness—Vincristine—kidney cancer	0.000153	0.00151	CcSEcCtD
Prazosin—Drowsiness—Doxorubicin—kidney cancer	0.000152	0.00151	CcSEcCtD
Prazosin—Feeling abnormal—Paclitaxel—kidney cancer	0.000151	0.0015	CcSEcCtD
Prazosin—Oedema—Capecitabine—kidney cancer	0.00015	0.00149	CcSEcCtD
Prazosin—Diarrhoea—Gemcitabine—kidney cancer	0.00015	0.00149	CcSEcCtD
Prazosin—Shock—Capecitabine—kidney cancer	0.000148	0.00147	CcSEcCtD
Prazosin—Tachycardia—Capecitabine—kidney cancer	0.000147	0.00146	CcSEcCtD
Prazosin—Vomiting—Vincristine—kidney cancer	0.000147	0.00146	CcSEcCtD
Prazosin—Urticaria—Paclitaxel—kidney cancer	0.000146	0.00144	CcSEcCtD
Prazosin—Rash—Vincristine—kidney cancer	0.000146	0.00144	CcSEcCtD
Prazosin—Hyperhidrosis—Capecitabine—kidney cancer	0.000145	0.00144	CcSEcCtD
Prazosin—Dermatitis—Vincristine—kidney cancer	0.000145	0.00144	CcSEcCtD
Prazosin—Body temperature increased—Paclitaxel—kidney cancer	0.000145	0.00144	CcSEcCtD
Prazosin—Headache—Vincristine—kidney cancer	0.000145	0.00143	CcSEcCtD
Prazosin—Epistaxis—Doxorubicin—kidney cancer	0.000143	0.00142	CcSEcCtD
Prazosin—Vomiting—Gemcitabine—kidney cancer	0.000139	0.00138	CcSEcCtD
Prazosin—Bradycardia—Doxorubicin—kidney cancer	0.000139	0.00138	CcSEcCtD
Prazosin—Rash—Gemcitabine—kidney cancer	0.000138	0.00137	CcSEcCtD
Prazosin—Dermatitis—Gemcitabine—kidney cancer	0.000138	0.00137	CcSEcCtD
Prazosin—Headache—Gemcitabine—kidney cancer	0.000137	0.00136	CcSEcCtD
Prazosin—Nausea—Vincristine—kidney cancer	0.000137	0.00136	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Capecitabine—kidney cancer	0.000137	0.00136	CcSEcCtD
Prazosin—Insomnia—Capecitabine—kidney cancer	0.000136	0.00135	CcSEcCtD
Prazosin—Paraesthesia—Capecitabine—kidney cancer	0.000135	0.00134	CcSEcCtD
Prazosin—Hypersensitivity—Paclitaxel—kidney cancer	0.000135	0.00134	CcSEcCtD
Prazosin—Dyspnoea—Capecitabine—kidney cancer	0.000134	0.00133	CcSEcCtD
Prazosin—Asthenia—Paclitaxel—kidney cancer	0.000132	0.0013	CcSEcCtD
Prazosin—Nausea—Gemcitabine—kidney cancer	0.00013	0.00129	CcSEcCtD
Prazosin—Fatigue—Capecitabine—kidney cancer	0.00013	0.00129	CcSEcCtD
Prazosin—Pruritus—Paclitaxel—kidney cancer	0.00013	0.00129	CcSEcCtD
Prazosin—Pain—Capecitabine—kidney cancer	0.000129	0.00128	CcSEcCtD
Prazosin—Constipation—Capecitabine—kidney cancer	0.000129	0.00128	CcSEcCtD
Prazosin—Tinnitus—Doxorubicin—kidney cancer	0.000127	0.00126	CcSEcCtD
Prazosin—Flushing—Doxorubicin—kidney cancer	0.000127	0.00126	CcSEcCtD
Prazosin—Diarrhoea—Paclitaxel—kidney cancer	0.000125	0.00124	CcSEcCtD
Prazosin—Feeling abnormal—Capecitabine—kidney cancer	0.000124	0.00123	CcSEcCtD
Prazosin—Dizziness—Paclitaxel—kidney cancer	0.000121	0.0012	CcSEcCtD
Prazosin—Alopecia—Doxorubicin—kidney cancer	0.000121	0.0012	CcSEcCtD
Prazosin—Urticaria—Capecitabine—kidney cancer	0.000119	0.00119	CcSEcCtD
Prazosin—Body temperature increased—Capecitabine—kidney cancer	0.000119	0.00118	CcSEcCtD
Prazosin—Tension—Doxorubicin—kidney cancer	0.000117	0.00116	CcSEcCtD
Prazosin—Vomiting—Paclitaxel—kidney cancer	0.000117	0.00116	CcSEcCtD
Prazosin—Rash—Paclitaxel—kidney cancer	0.000116	0.00115	CcSEcCtD
Prazosin—Dermatitis—Paclitaxel—kidney cancer	0.000115	0.00115	CcSEcCtD
Prazosin—Nervousness—Doxorubicin—kidney cancer	0.000115	0.00114	CcSEcCtD
Prazosin—Headache—Paclitaxel—kidney cancer	0.000115	0.00114	CcSEcCtD
Prazosin—Vision blurred—Doxorubicin—kidney cancer	0.000112	0.00111	CcSEcCtD
Prazosin—Hypersensitivity—Capecitabine—kidney cancer	0.000111	0.0011	CcSEcCtD
Prazosin—Ill-defined disorder—Doxorubicin—kidney cancer	0.00011	0.00109	CcSEcCtD
Prazosin—Nausea—Paclitaxel—kidney cancer	0.000109	0.00108	CcSEcCtD
Prazosin—Asthenia—Capecitabine—kidney cancer	0.000108	0.00107	CcSEcCtD
Prazosin—Malaise—Doxorubicin—kidney cancer	0.000107	0.00106	CcSEcCtD
Prazosin—Vertigo—Doxorubicin—kidney cancer	0.000107	0.00106	CcSEcCtD
Prazosin—Syncope—Doxorubicin—kidney cancer	0.000107	0.00106	CcSEcCtD
Prazosin—Pruritus—Capecitabine—kidney cancer	0.000106	0.00106	CcSEcCtD
Prazosin—Palpitations—Doxorubicin—kidney cancer	0.000105	0.00104	CcSEcCtD
Prazosin—Loss of consciousness—Doxorubicin—kidney cancer	0.000104	0.00104	CcSEcCtD
Prazosin—Diarrhoea—Capecitabine—kidney cancer	0.000103	0.00102	CcSEcCtD
Prazosin—Arthralgia—Doxorubicin—kidney cancer	0.000101	0.001	CcSEcCtD
Prazosin—Discomfort—Doxorubicin—kidney cancer	9.99e-05	0.000991	CcSEcCtD
Prazosin—Dizziness—Capecitabine—kidney cancer	9.95e-05	0.000987	CcSEcCtD
Prazosin—Dry mouth—Doxorubicin—kidney cancer	9.89e-05	0.000981	CcSEcCtD
Prazosin—Oedema—Doxorubicin—kidney cancer	9.7e-05	0.000962	CcSEcCtD
Prazosin—Vomiting—Capecitabine—kidney cancer	9.56e-05	0.000949	CcSEcCtD
Prazosin—Shock—Doxorubicin—kidney cancer	9.54e-05	0.000946	CcSEcCtD
Prazosin—Rash—Capecitabine—kidney cancer	9.48e-05	0.000941	CcSEcCtD
Prazosin—Dermatitis—Capecitabine—kidney cancer	9.47e-05	0.00094	CcSEcCtD
Prazosin—Tachycardia—Doxorubicin—kidney cancer	9.46e-05	0.000939	CcSEcCtD
Prazosin—Headache—Capecitabine—kidney cancer	9.42e-05	0.000935	CcSEcCtD
Prazosin—Hyperhidrosis—Doxorubicin—kidney cancer	9.37e-05	0.00093	CcSEcCtD
Prazosin—Nausea—Capecitabine—kidney cancer	8.93e-05	0.000886	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Doxorubicin—kidney cancer	8.83e-05	0.000876	CcSEcCtD
Prazosin—Insomnia—Doxorubicin—kidney cancer	8.77e-05	0.00087	CcSEcCtD
Prazosin—Paraesthesia—Doxorubicin—kidney cancer	8.71e-05	0.000864	CcSEcCtD
Prazosin—Dyspnoea—Doxorubicin—kidney cancer	8.64e-05	0.000858	CcSEcCtD
Prazosin—Somnolence—Doxorubicin—kidney cancer	8.62e-05	0.000855	CcSEcCtD
Prazosin—Fatigue—Doxorubicin—kidney cancer	8.36e-05	0.000829	CcSEcCtD
Prazosin—Constipation—Doxorubicin—kidney cancer	8.29e-05	0.000823	CcSEcCtD
Prazosin—Pain—Doxorubicin—kidney cancer	8.29e-05	0.000823	CcSEcCtD
Prazosin—Feeling abnormal—Doxorubicin—kidney cancer	7.99e-05	0.000793	CcSEcCtD
Prazosin—Urticaria—Doxorubicin—kidney cancer	7.7e-05	0.000764	CcSEcCtD
Prazosin—Body temperature increased—Doxorubicin—kidney cancer	7.66e-05	0.00076	CcSEcCtD
Prazosin—Hypersensitivity—Doxorubicin—kidney cancer	7.14e-05	0.000709	CcSEcCtD
Prazosin—Asthenia—Doxorubicin—kidney cancer	6.96e-05	0.00069	CcSEcCtD
Prazosin—Pruritus—Doxorubicin—kidney cancer	6.86e-05	0.000681	CcSEcCtD
Prazosin—Diarrhoea—Doxorubicin—kidney cancer	6.63e-05	0.000658	CcSEcCtD
Prazosin—Dizziness—Doxorubicin—kidney cancer	6.41e-05	0.000636	CcSEcCtD
Prazosin—Vomiting—Doxorubicin—kidney cancer	6.16e-05	0.000612	CcSEcCtD
Prazosin—Rash—Doxorubicin—kidney cancer	6.11e-05	0.000607	CcSEcCtD
Prazosin—Dermatitis—Doxorubicin—kidney cancer	6.11e-05	0.000606	CcSEcCtD
Prazosin—Headache—Doxorubicin—kidney cancer	6.07e-05	0.000603	CcSEcCtD
Prazosin—Nausea—Doxorubicin—kidney cancer	5.76e-05	0.000571	CcSEcCtD
Prazosin—ADRA2A—Hemostasis—MAPK1—kidney cancer	5.93e-06	0.000121	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—KDR—kidney cancer	5.92e-06	0.000121	CbGpPWpGaD
Prazosin—ADRA2B—Signaling by GPCR—IL2—kidney cancer	5.86e-06	0.00012	CbGpPWpGaD
Prazosin—HTR1D—Signaling by GPCR—MAPK1—kidney cancer	5.8e-06	0.000118	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	5.75e-06	0.000117	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—IGF2—kidney cancer	5.73e-06	0.000117	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—CDKN2B—kidney cancer	5.71e-06	0.000116	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—CYP1A1—kidney cancer	5.7e-06	0.000116	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—BCHE—kidney cancer	5.69e-06	0.000116	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—GSTP1—kidney cancer	5.67e-06	0.000116	CbGpPWpGaD
Prazosin—HTR1A—Signaling by GPCR—IL2—kidney cancer	5.66e-06	0.000116	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—SLC5A5—kidney cancer	5.62e-06	0.000115	CbGpPWpGaD
Prazosin—ADRA2A—Hemostasis—KRAS—kidney cancer	5.6e-06	0.000114	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—HIF1A—kidney cancer	5.59e-06	0.000114	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—TSC2—kidney cancer	5.57e-06	0.000114	CbGpPWpGaD
Prazosin—HTR1D—GPCR downstream signaling—PIK3CA—kidney cancer	5.55e-06	0.000113	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—IGF1R—kidney cancer	5.54e-06	0.000113	CbGpPWpGaD
Prazosin—HTR1D—Signaling by GPCR—KRAS—kidney cancer	5.48e-06	0.000112	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—APC—kidney cancer	5.45e-06	0.000111	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—KIT—kidney cancer	5.45e-06	0.000111	CbGpPWpGaD
Prazosin—ABCG2—Metabolism—POMC—kidney cancer	5.44e-06	0.000111	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—SLC2A1—kidney cancer	5.43e-06	0.000111	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—HIF1A—kidney cancer	5.39e-06	0.00011	CbGpPWpGaD
Prazosin—ADRA1B—Signaling by GPCR—IL2—kidney cancer	5.39e-06	0.00011	CbGpPWpGaD
Prazosin—SLC22A2—Metabolism—POMC—kidney cancer	5.38e-06	0.00011	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—TSC2—kidney cancer	5.38e-06	0.00011	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—ABCB1—kidney cancer	5.36e-06	0.000109	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—KDR—kidney cancer	5.34e-06	0.000109	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—RAF1—kidney cancer	5.34e-06	0.000109	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—IGF2—kidney cancer	5.32e-06	0.000109	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—CDKN2B—kidney cancer	5.3e-06	0.000108	CbGpPWpGaD
Prazosin—ADRA1A—GPCR downstream signaling—IL2—kidney cancer	5.27e-06	0.000108	CbGpPWpGaD
Prazosin—ADRA1D—Signaling by GPCR—MAPK3—kidney cancer	5.22e-06	0.000107	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—GSTM1—kidney cancer	5.21e-06	0.000106	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—POMC—kidney cancer	5.19e-06	0.000106	CbGpPWpGaD
Prazosin—ABCB1—Transmembrane transport of small molecules—RAF1—kidney cancer	5.17e-06	0.000106	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—KDR—kidney cancer	5.16e-06	0.000105	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—IGF1R—kidney cancer	5.15e-06	0.000105	CbGpPWpGaD
Prazosin—ADRA2A—Hemostasis—PIK3CA—kidney cancer	5.14e-06	0.000105	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—HIF1A—kidney cancer	5.14e-06	0.000105	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—BRAF—kidney cancer	5.12e-06	0.000105	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—TSC2—kidney cancer	5.12e-06	0.000105	CbGpPWpGaD
Prazosin—HTR1D—Signaling by GPCR—PIK3CA—kidney cancer	5.04e-06	0.000103	CbGpPWpGaD
Prazosin—SLC22A1—Metabolism—POMC—kidney cancer	5.01e-06	0.000102	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—RAF1—kidney cancer	5e-06	0.000102	CbGpPWpGaD
Prazosin—ADRA2A—Hemostasis—TP53—kidney cancer	4.98e-06	0.000102	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—RELA—kidney cancer	4.98e-06	0.000102	CbGpPWpGaD
Prazosin—ADRA1D—Signaling by GPCR—MAPK1—kidney cancer	4.97e-06	0.000101	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—RAF1—kidney cancer	4.96e-06	0.000101	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—ERBB2—kidney cancer	4.95e-06	0.000101	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—APC—kidney cancer	4.92e-06	0.0001	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—KIT—kidney cancer	4.92e-06	0.0001	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—KDR—kidney cancer	4.91e-06	0.0001	CbGpPWpGaD
Prazosin—ADRA2A—GPCR downstream signaling—IL2—kidney cancer	4.9e-06	0.0001	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—MTOR—kidney cancer	4.88e-06	9.96e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—IL2—kidney cancer	4.79e-06	9.77e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—APC—kidney cancer	4.75e-06	9.7e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—KIT—kidney cancer	4.75e-06	9.7e-05	CbGpPWpGaD
Prazosin—ADRA1D—GPCR downstream signaling—PIK3CA—kidney cancer	4.75e-06	9.69e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling by GPCR—MAPK3—kidney cancer	4.71e-06	9.62e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling by GPCR—KRAS—kidney cancer	4.69e-06	9.58e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—POMC—kidney cancer	4.68e-06	9.56e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—BRAF—kidney cancer	4.63e-06	9.44e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—CDKN1B—kidney cancer	4.58e-06	9.35e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—HIF1A—kidney cancer	4.56e-06	9.31e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—TSC2—kidney cancer	4.55e-06	9.29e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling by GPCR—MAPK3—kidney cancer	4.55e-06	9.29e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—GSTP1—kidney cancer	4.53e-06	9.24e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—APC—kidney cancer	4.52e-06	9.23e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—KIT—kidney cancer	4.52e-06	9.23e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—POMC—kidney cancer	4.52e-06	9.23e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling by GPCR—MAPK1—kidney cancer	4.48e-06	9.15e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—IL2—kidney cancer	4.48e-06	9.15e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—BRAF—kidney cancer	4.47e-06	9.11e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—IL2—kidney cancer	4.45e-06	9.08e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—CCND1—kidney cancer	4.37e-06	8.92e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—KDR—kidney cancer	4.36e-06	8.9e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—JUN—kidney cancer	4.36e-06	8.9e-05	CbGpPWpGaD
Prazosin—ABCG2—Metabolism—PTGS2—kidney cancer	4.34e-06	8.85e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling by GPCR—MAPK3—kidney cancer	4.33e-06	8.84e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling by GPCR—MAPK1—kidney cancer	4.33e-06	8.84e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—CTNNB1—kidney cancer	4.33e-06	8.83e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling by GPCR—PIK3CA—kidney cancer	4.31e-06	8.8e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—POMC—kidney cancer	4.31e-06	8.79e-05	CbGpPWpGaD
Prazosin—SLC22A2—Metabolism—PTGS2—kidney cancer	4.29e-06	8.76e-05	CbGpPWpGaD
Prazosin—ADRA2B—GPCR downstream signaling—PIK3CA—kidney cancer	4.28e-06	8.75e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—RAF1—kidney cancer	4.28e-06	8.73e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—RELA—kidney cancer	4.26e-06	8.69e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—BRAF—kidney cancer	4.25e-06	8.68e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—POMC—kidney cancer	4.25e-06	8.68e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—HIF1A—kidney cancer	4.24e-06	8.65e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling by GPCR—KRAS—kidney cancer	4.24e-06	8.64e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—ERBB2—kidney cancer	4.23e-06	8.64e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—TSC2—kidney cancer	4.23e-06	8.63e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—PTEN—kidney cancer	4.22e-06	8.61e-05	CbGpPWpGaD
Prazosin—SLC22A3—Metabolism—PIK3CA—kidney cancer	4.21e-06	8.59e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—MTOR—kidney cancer	4.18e-06	8.52e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—GSTM1—kidney cancer	4.16e-06	8.49e-05	CbGpPWpGaD
Prazosin—HTR1A—GPCR downstream signaling—PIK3CA—kidney cancer	4.14e-06	8.44e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling by GPCR—MAPK1—kidney cancer	4.12e-06	8.41e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling by GPCR—KRAS—kidney cancer	4.09e-06	8.35e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	4.05e-06	8.28e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—KDR—kidney cancer	4.05e-06	8.27e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—APC—kidney cancer	4.02e-06	8.2e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—KIT—kidney cancer	4.02e-06	8.2e-05	CbGpPWpGaD
Prazosin—SLC22A1—Metabolism—PTGS2—kidney cancer	4e-06	8.16e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—CYP1A1—kidney cancer	3.94e-06	8.05e-05	CbGpPWpGaD
Prazosin—ADRA1B—GPCR downstream signaling—PIK3CA—kidney cancer	3.94e-06	8.04e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—CDKN1B—kidney cancer	3.92e-06	8e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling by GPCR—KRAS—kidney cancer	3.89e-06	7.95e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling by GPCR—PIK3CA—kidney cancer	3.89e-06	7.94e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—RAF1—kidney cancer	3.86e-06	7.88e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—MAPK3—kidney cancer	3.85e-06	7.86e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—RELA—kidney cancer	3.85e-06	7.85e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—IL2—kidney cancer	3.84e-06	7.83e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—POMC—kidney cancer	3.83e-06	7.81e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—ERBB2—kidney cancer	3.82e-06	7.8e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—VEGFA—kidney cancer	3.81e-06	7.77e-05	CbGpPWpGaD
Prazosin—ABCG2—Metabolism—PTEN—kidney cancer	3.78e-06	7.72e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—BRAF—kidney cancer	3.78e-06	7.71e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—MTOR—kidney cancer	3.77e-06	7.7e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling by GPCR—PIK3CA—kidney cancer	3.76e-06	7.67e-05	CbGpPWpGaD
Prazosin—SLC22A2—Metabolism—PTEN—kidney cancer	3.74e-06	7.64e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—CCND1—kidney cancer	3.74e-06	7.63e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—APC—kidney cancer	3.73e-06	7.62e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—KIT—kidney cancer	3.73e-06	7.62e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—JUN—kidney cancer	3.73e-06	7.62e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—RAF1—kidney cancer	3.73e-06	7.61e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—RELA—kidney cancer	3.71e-06	7.58e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—CTNNB1—kidney cancer	3.7e-06	7.56e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—ERBB2—kidney cancer	3.69e-06	7.53e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—POMC—kidney cancer	3.68e-06	7.51e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—MAPK1—kidney cancer	3.66e-06	7.47e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—MTOR—kidney cancer	3.64e-06	7.43e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—PTEN—kidney cancer	3.61e-06	7.37e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—MAPK3—kidney cancer	3.6e-06	7.35e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling by GPCR—PIK3CA—kidney cancer	3.58e-06	7.3e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—MAPK3—kidney cancer	3.58e-06	7.3e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—POMC—kidney cancer	3.55e-06	7.25e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—RAF1—kidney cancer	3.55e-06	7.25e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—CDKN1B—kidney cancer	3.54e-06	7.22e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—RELA—kidney cancer	3.53e-06	7.22e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—ERBB2—kidney cancer	3.51e-06	7.17e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—BRAF—kidney cancer	3.51e-06	7.16e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—MYC—kidney cancer	3.5e-06	7.15e-05	CbGpPWpGaD
Prazosin—ADRA1A—GPCR downstream signaling—PIK3CA—kidney cancer	3.5e-06	7.14e-05	CbGpPWpGaD
Prazosin—SLC22A1—Metabolism—PTEN—kidney cancer	3.49e-06	7.12e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—MTOR—kidney cancer	3.47e-06	7.08e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—IL2—kidney cancer	3.46e-06	7.07e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—KRAS—kidney cancer	3.46e-06	7.06e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—MAPK1—kidney cancer	3.43e-06	7e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—CDKN1B—kidney cancer	3.42e-06	6.97e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—MAPK1—kidney cancer	3.4e-06	6.94e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—PTGS2—kidney cancer	3.39e-06	6.92e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—CCND1—kidney cancer	3.38e-06	6.89e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—JUN—kidney cancer	3.37e-06	6.88e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—CTNNB1—kidney cancer	3.34e-06	6.82e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—IL2—kidney cancer	3.34e-06	6.82e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—VEGFA—kidney cancer	3.26e-06	6.65e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—CCND1—kidney cancer	3.26e-06	6.65e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—PTEN—kidney cancer	3.26e-06	6.65e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—CDKN1B—kidney cancer	3.25e-06	6.64e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—JUN—kidney cancer	3.25e-06	6.64e-05	CbGpPWpGaD
Prazosin—ADRA2A—GPCR downstream signaling—PIK3CA—kidney cancer	3.25e-06	6.64e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—KRAS—kidney cancer	3.24e-06	6.61e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—CTNNB1—kidney cancer	3.23e-06	6.59e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—KRAS—kidney cancer	3.21e-06	6.56e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—IL2—kidney cancer	3.18e-06	6.5e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—PIK3CA—kidney cancer	3.18e-06	6.49e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—RAF1—kidney cancer	3.15e-06	6.44e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—PTEN—kidney cancer	3.15e-06	6.42e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—RELA—kidney cancer	3.14e-06	6.41e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—ERBB2—kidney cancer	3.12e-06	6.37e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—CCND1—kidney cancer	3.1e-06	6.33e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—JUN—kidney cancer	3.1e-06	6.32e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—MAPK3—kidney cancer	3.08e-06	6.29e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—MTOR—kidney cancer	3.08e-06	6.28e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—CTNNB1—kidney cancer	3.07e-06	6.27e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—MYC—kidney cancer	3e-06	6.12e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—PTEN—kidney cancer	3e-06	6.11e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—PIK3CA—kidney cancer	2.97e-06	6.07e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—PTEN—kidney cancer	2.96e-06	6.03e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—PIK3CA—kidney cancer	2.95e-06	6.03e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—VEGFA—kidney cancer	2.94e-06	6.01e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—POMC—kidney cancer	2.94e-06	6e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—PTGS2—kidney cancer	2.94e-06	5.99e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—MAPK1—kidney cancer	2.93e-06	5.99e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—RAF1—kidney cancer	2.93e-06	5.98e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—RELA—kidney cancer	2.92e-06	5.95e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—ERBB2—kidney cancer	2.9e-06	5.92e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—CDKN1B—kidney cancer	2.89e-06	5.9e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—TP53—kidney cancer	2.88e-06	5.87e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—MTOR—kidney cancer	2.86e-06	5.84e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—VEGFA—kidney cancer	2.84e-06	5.8e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—IL2—kidney cancer	2.83e-06	5.77e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—MAPK3—kidney cancer	2.78e-06	5.68e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—KRAS—kidney cancer	2.77e-06	5.66e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—CCND1—kidney cancer	2.76e-06	5.63e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—JUN—kidney cancer	2.75e-06	5.61e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—CTNNB1—kidney cancer	2.73e-06	5.57e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—MYC—kidney cancer	2.71e-06	5.53e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—VEGFA—kidney cancer	2.71e-06	5.52e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—MAPK3—kidney cancer	2.69e-06	5.49e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—CDKN1B—kidney cancer	2.68e-06	5.48e-05	CbGpPWpGaD
Prazosin—ABCG2—Metabolism—PIK3CA—kidney cancer	2.67e-06	5.44e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—PTEN—kidney cancer	2.66e-06	5.43e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—MAPK1—kidney cancer	2.65e-06	5.41e-05	CbGpPWpGaD
Prazosin—SLC22A2—Metabolism—PIK3CA—kidney cancer	2.64e-06	5.39e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—IL2—kidney cancer	2.63e-06	5.36e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—MYC—kidney cancer	2.61e-06	5.34e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—CCND1—kidney cancer	2.56e-06	5.23e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—PTEN—kidney cancer	2.56e-06	5.22e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—MAPK3—kidney cancer	2.56e-06	5.22e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—MAPK1—kidney cancer	2.56e-06	5.22e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—JUN—kidney cancer	2.56e-06	5.22e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—PIK3CA—kidney cancer	2.55e-06	5.2e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—CTNNB1—kidney cancer	2.54e-06	5.18e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—KRAS—kidney cancer	2.5e-06	5.11e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—MYC—kidney cancer	2.49e-06	5.08e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—PTEN—kidney cancer	2.47e-06	5.05e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—TP53—kidney cancer	2.46e-06	5.03e-05	CbGpPWpGaD
Prazosin—SLC22A1—Metabolism—PIK3CA—kidney cancer	2.46e-06	5.02e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—MAPK1—kidney cancer	2.44e-06	4.97e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—KRAS—kidney cancer	2.42e-06	4.93e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—VEGFA—kidney cancer	2.4e-06	4.91e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—PTGS2—kidney cancer	2.34e-06	4.78e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—KRAS—kidney cancer	2.3e-06	4.69e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—PIK3CA—kidney cancer	2.3e-06	4.69e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—MAPK3—kidney cancer	2.27e-06	4.64e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—VEGFA—kidney cancer	2.23e-06	4.56e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—TP53—kidney cancer	2.22e-06	4.54e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—PIK3CA—kidney cancer	2.22e-06	4.53e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—MYC—kidney cancer	2.21e-06	4.51e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—MAPK1—kidney cancer	2.16e-06	4.42e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—TP53—kidney cancer	2.15e-06	4.38e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—PIK3CA—kidney cancer	2.11e-06	4.31e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—MAPK3—kidney cancer	2.11e-06	4.31e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—PIK3CA—kidney cancer	2.09e-06	4.26e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—MYC—kidney cancer	2.05e-06	4.19e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—PTEN—kidney cancer	2.04e-06	4.17e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—TP53—kidney cancer	2.04e-06	4.17e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—KRAS—kidney cancer	2.04e-06	4.17e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—MAPK1—kidney cancer	2.01e-06	4.1e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—KRAS—kidney cancer	1.9e-06	3.87e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—PIK3CA—kidney cancer	1.88e-06	3.83e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—TP53—kidney cancer	1.82e-06	3.71e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—PIK3CA—kidney cancer	1.81e-06	3.69e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—PIK3CA—kidney cancer	1.74e-06	3.56e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—TP53—kidney cancer	1.69e-06	3.44e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—PIK3CA—kidney cancer	1.44e-06	2.94e-05	CbGpPWpGaD
